Eikon Therapeutics

Eikon Therapeutics, Inc. announced that it had acquired exclusive rights to multiple assets.

Eikon Therapeutics, Inc. announced the appointment of Robert (“Robbie”) L. Huffines as an independent director.

Eikon Therapeutics, Inc. is a clinical-stage biotechnology company integrating engineering and science to advance therapeutics. It announced its Clinical Development organization.

Eikon Therapeutics opened its second location in Hayward to expand its research and engineering infrastructure.

Alfred “Freddie” Bowie is Chief Financial Officer of Eikon Therapeutics and leads finance, corporate strategy, investor relations, corporate communications, procurement, clinical supply, and real estate.

Ashish Kheterpal is Chief Information Officer of Eikon Therapeutics and leads its information technology function, including IT strategy, infrastructure, operations, and security.

Barbara Howes is Chief People Officer of Eikon Therapeutics and leads the company’s people strategy, including talent, diversity, culture, and employee engagement.

Dan Anderson is Chief Scientific Officer of Eikon Therapeutics and leads the company’s research and drug discovery functions.

Advancing breakthrough therapeutics through the purposeful integration of science and engineering

Advancing breakthrough therapeutics through the purposeful integration of engineering and science.

Eikon Therapeutics appoints Ching-Pin Chang, M.D., Ph.D., as executive vice president and chief scientific officer. The company announces the appointment on September 3, 2026.

Sep 2026 · GlobeNewswireNews article

Eikon Therapeutics reports second-quarter 2026 financial results and clinical updates, ending the quarter with $531.2 million in cash, cash equivalents, and marketable securities. Clinical highlights include seven abstracts accepted at ESMO 2026, ASCO 2026 data for EIK1001 and EIK1003, and the TeLuRide-006 registrational trial advancing through a first interim analysis.

Aug 2026 · GlobeNewswireNews article

Eikon Therapeutics selects 0.60 mg/m2 as the dose going forward for EIK1001 in TeLuRide-006, its ongoing adaptive Phase 2/3 trial in advanced melanoma. The trial evaluates the TLR7/8 dual agonist in combination with pembrolizumab as first-line therapy for patients with advanced melanoma.

Aug 2026 · GlobeNewswireNews article

Eikon Therapeutics has dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 for treatment-naive patients with stage 4 non-small cell lung cancer. The study evaluates EIK1001, a TLR7/8 dual agonist, with pembrolizumab and histology-appropriate chemotherapy as first-line therapy.

Jul 2026 · GlobeNewswireNews article